Patents Assigned to Centers For Disease Control and Prevention
  • Patent number: 9063150
    Abstract: Disclosed herein is a rapid and universal assay for the detection of antigen-specific antibodies in biological samples. The assay allows for the detection of antigen-specific antibodies in any species, including species for which secondary antibodies or antisera have not been developed or are not available. Biological samples to be tested are directly labeled, such as with biotin, and contacted with antigen-bound microparticles. The presence of antigen-specific antibodies in the biological samples is detected using a binding partner for the label, such as a biotin binding partner, conjugated to a detectable label, such as a fluorophore. This improved test provides a total antibody assay that is capable of detecting all classes of antibodies simultaneously.
    Type: Grant
    Filed: August 25, 2009
    Date of Patent: June 23, 2015
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control Prevention
    Inventor: Alison Jane Basile
  • Patent number: 9046520
    Abstract: Regions of Bacillus anthracis protective antigen are provided representing epitopes recognized by antibodies in subjects that have acquired immunity to Bacillus anthracis infection. The recognition of these epitopes correlates with autoimmunity in a subject. Also provided are vaccines that include at least one of these epitopes that when administered to a subject provide improved acquired immunity.
    Type: Grant
    Filed: February 10, 2011
    Date of Patent: June 2, 2015
    Assignee: The United States of America, as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Vera A. Semenova, Conrad P. Quinn, Jan Pohl, Pavel Svoboda
  • Patent number: 9045777
    Abstract: The present invention relates to a pol I promoter derived from Vero cells and a recombinant vector containing the same. When the pol I promoter derived from Vero cells according to the present invention is utilized, viruses can be manufactured efficiently, and consequently, the manufacture of both seasonal influenza vaccine and pandemic vaccine can be prepared more quickly to usefully address either situation.
    Type: Grant
    Filed: September 17, 2013
    Date of Patent: June 2, 2015
    Assignees: Korea Center for Disease Control and Prevention, Chungbuk National University Industry-Academic Cooperation Foundation
    Inventors: Young Ki Choi, Chun Kang, Kee Jong Hong, Min Suk Song, Yun Hee Baek
  • Patent number: 9040244
    Abstract: Provided herein are new methods, primers, and kits for genotyping HIV-1, including group M viral strains. The methods can be used for HIV-1 drug resistance surveillance and monitoring, for example in resource-poor countries. The disclosed methods can detected more mixed HIV-1 population than previous methods. Given the high efficiency in genotyping diverse HIV-1 group M viral strains from plasma and dried blood spot (DBS) samples and substantial reagent cost saving, the disclosed methods can be used for HIV-1 drug resistance genotyping in both antiretroviral therapy (ART)-naive and -experienced populations for surveillance purposes and patient monitoring.
    Type: Grant
    Filed: July 5, 2012
    Date of Patent: May 26, 2015
    Assignee: The United States of America as Represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Chunfu Yang, Zhiyong Zhou, Nicholas Wagar, Joshua R. DeVos
  • Patent number: 9000141
    Abstract: Disclosed herein is a method for identifying flavivirus cross-reactive epitopes. Also provided are flavivirus E-glycoprotein cross-reactive epitopes and flavivirus E-glycoprotein cross-reactive epitopes having reduced or ablated cross-reactivity (and polypeptides comprising such epitopes), as well as methods of using these molecules to elicit an immune response against a flavivirus and to detect a flaviviral infection.
    Type: Grant
    Filed: September 28, 2010
    Date of Patent: April 7, 2015
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Gwong-Jen J. Chang, Wayne D. Crill
  • Patent number: 8970840
    Abstract: Particles of a flow of aerosol are collected and analyzed by passing them through a housing having an inlet area, an outlet area, and a collection and analysis area interconnecting the inlet and outlet areas. A collection electrode has a tip disposed in the collection and analysis area and particles are collected thereon. After collection, the particles are ablated and atomic emissions are collected for analysis of the particles.
    Type: Grant
    Filed: December 9, 2011
    Date of Patent: March 3, 2015
    Assignee: The United States of America, as Represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Pramod Kulkarni, Prasoon Diwakar
  • Patent number: 8956620
    Abstract: Provided are antigenic polypeptides of HIV envelope glycoproteins which are constructed based on amino acid mutation of attenuated live vaccine of Equine Infectious Anemia Virus, DNA constructions and recombinant virus vectors comprising polynucleotides encoding said polypeptides, antibodies against said polypeptides as well as uses thereof in preventing and treating HIV infection. Said antigenic polypeptides and vaccines can induce high titer neutralization antibodies against HIV in organism.
    Type: Grant
    Filed: May 27, 2009
    Date of Patent: February 17, 2015
    Assignee: National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention
    Inventors: Yiming Shao, Lianxing Liu, Rongxian Shen
  • Patent number: 8942662
    Abstract: A miniaturized, ruggedized, field-deployable Portable Exposure Assessment System (PEAS) is used to remotely monitor workers and provide real-time warning of exposure to musculoskeletal injury conditions via alarm and smart-phone transmission. The PEAS unit wirelessly acquires exposure data from sensors; conducts initial data analysis; triggers proximal and remote alarms; sends out text messages with abnormal data, GPS locations, and time stamps to a safety office; and saves data for more extensive assessment. Sensor technology is used in this field-deployable system to simultaneously measure and collect the body loads and awkward postures imposed by package handling as well as driving-related, low-frequency vibration exposures. Wireless technology is used to set up wireless communication links between the sensors and a data logger and between the data logger and a smart phone with GPS, date/time stamp and text messaging capabilities.
    Type: Grant
    Filed: February 15, 2013
    Date of Patent: January 27, 2015
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services, Center for Disease Control and Prevention
    Inventors: Christopher S. Pan, Shengke Zeng, Bryan Wimer
  • Publication number: 20150004132
    Abstract: We have developed DNA and viral vectors that can be used, alone or in combination, as a vaccine against one HIV clade, subtype, or recombinant form of HIV or against multiple HIV clades, subtypes, or recombinant forms. Moreover, the vectors can encode a variety of antigens, which may be obtained from one clade or from two or more different clades, and the antigens selected and/or the manner in which the vectors are formulated (e.g., mixed) can be manipulated to generate a protective immune response against a variety of clades (e.g., the clades to which a patient is most likely to be exposed; with the proportions of the components of the vaccine tailored to the extent of the patient's risk to a particular clade or clades).
    Type: Application
    Filed: December 20, 2013
    Publication date: January 1, 2015
    Applicants: EMORY UNIVERSITY, Centers for Disease Control and Prevention, The United States of America as Represented by the Department of Health and Human Services
    Inventors: Harriet Robinson, James Smith, Ram Amara, Bernard Moss, Salvatore T. Butera, Dennis Ellenberger
  • Patent number: 8906603
    Abstract: Compositions, methods and devices for the detection of anti-lipoidal antibodies and the diagnosis of disease, for example, syphilis, are described. In particular, oxidized cardiolipins, which may be conjugated with a variety of attachment molecules, such as BSA, KLH, biotin, synthetic protein MAPS, IgY, streptavidin, or avidin, are described. Such oxidized cardiolipin, alone or complexed with one or more attachment molecules, are useful to detect anti-lipoidal antibodies in subjects, for example, when used in lateral flow devices. Lateral flow devices are described that permit the detection of anti-lipoidal antibodies and that permit the co-detection of nontreponemal and treponemal antibodies in biological samples.
    Type: Grant
    Filed: February 14, 2011
    Date of Patent: December 9, 2014
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Arnold R. Castro, Huiying Wang
  • Patent number: 8875702
    Abstract: A sonic aerosol generator is provided that provides a constant concentration of particulate aerosol over a long exposure time to an animal. The concentration of aerosols is maintainable for greater than 30 hours at concentrations of 15 mg/m3 or more. The aerosol generator is used to expose subject to high concentrations of aerosols that more accurately represents the levels that may be seen in a workplace environment.
    Type: Grant
    Filed: August 30, 2010
    Date of Patent: November 4, 2014
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Walter McKinney, Dave Frazer, Bean Chen
  • Patent number: 8865461
    Abstract: Rabies Virus compositions and methods are provided. The full-length sequence of Rabies Virus strain Evelyn-Rokitnicki-Abelseth (ERA) is disclosed. A reverse genetics system for producing recombinant ERA virus and derivatives thereof is provided, along with compositions including ERA and/or ERA derivative strain viruses, nucleic acids and/or proteins. In some instances, the compositions are immunogenic compositions useful for the pre- or post-exposure treatment of Rabies Virus.
    Type: Grant
    Filed: November 30, 2010
    Date of Patent: October 21, 2014
    Assignee: The United States of America as represtented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Charles E. Rupprecht, Xianfu Wu
  • Patent number: 8859742
    Abstract: This disclosure relates to compositions and methods of their use in detection and identification of a chordopoxvirus in a sample, such as diagnosis of an infection in a subject. The compositions and methods allow for detection and identification of all non-avian low-GC content chordopoxviruses, identification of most known high-GC content chordopoxvirus, and species-specific detection of Canarypox virus, Fowlpox virus, and Sealpox virus.
    Type: Grant
    Filed: November 2, 2010
    Date of Patent: October 14, 2014
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Yu Li, Inger K. Damon, Hui Zhao
  • Patent number: 8846051
    Abstract: Methods of producing a pathogen with reduced replicative fitness are disclosed, as are attenuated pathogens produced using the methods. In particular examples, the method includes deoptimizing one or more codons in a coding sequence, thereby reducing the replicative fitness of the pathogen. Methods of using the attenuated pathogens as immunogenic compositions are also disclosed.
    Type: Grant
    Filed: October 7, 2005
    Date of Patent: September 30, 2014
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Olen M. Kew, Cara C. Burns, Jing Shaw, Raymond Campagnoli, Jacqueline Quay
  • Patent number: 8835117
    Abstract: Methods of detecting Chlamydophila, including differentiating between species of Chlamydophila and/or strains of Chlamydophila psittaci are disclosed, for example to detect and genotype a Chlamydophila psittaci infection. A sample suspected of containing a nucleic acid of a Chlamydophila, is screened for the presence of that nucleic acid. The presence of the Chlamydophila nucleic acid indicates the presence of the Chlamydophila bacterium. Determining whether a Chlamydophila nucleic acid is present in a sample can be accomplished by detecting hybridization between a Chlamydophila specific primer, a Chlamydophila psittaci specific primer, and/or a Chlamydophila psittaci genotype-specific primer and the Chlamydophila nucleic acid containing sample. Thus, primers for the detection, species-specific and/or genotype-specific identification of Chlamydophila psittaci are disclosed. Kits that contain the disclosed primers also are disclosed.
    Type: Grant
    Filed: May 28, 2010
    Date of Patent: September 16, 2014
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Stephanie L. Mitchell, Jonas M. Winchell
  • Patent number: 8835164
    Abstract: Disclosed are a cell line that expresses protein of Seq. No. 1, and a method for screening an anticancer compound of uterine cervical cancer by using the same. The stable cell line that expresses oncoprotein E6 of a human papillomavirus type 16 variant strain is used to determine a difference in amounts of expression of tumor suppressor genes, such as p53, between E6 protein of the reference strain and E6 protein of a variant strain, thereby screening an anticancer compound of uterine cervical cancer, etc. Further, it is possible to develop an anticancer agent of uterine cervical cancer.
    Type: Grant
    Filed: June 7, 2010
    Date of Patent: September 16, 2014
    Assignee: Korea Center for Disease Control and Prevention
    Inventors: Jee Eun Rhee, Dae Ho Jang, Sung Soon Kim, Byeong Sun Choi
  • Patent number: 8821409
    Abstract: A device for collecting material from lung aerosols. The device functions by collecting aerosols from the lower airway separated from material in the by collecting air from the upper airway in a chamber that when full causes the remaining exhaled aerosols from the lungs to be captured by a filter. The filter collects sample of material from the separated lung aerosols.
    Type: Grant
    Filed: December 21, 2009
    Date of Patent: September 2, 2014
    Assignees: The United States of America as Represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention, Georgia Tech Research Corporation
    Inventors: David N. Ku, Larry J. Anderson, Prem A. Midha, Harris L. Bergman, Tamera Scholz
  • Publication number: 20140223802
    Abstract: Improved devices for the capture, detection, or quantification of insect vectors such as gravid female insects, are provided. The devices include surface coloration, design, and dimension that improved their ability to attract and/or capture target insect vectors. The traps are used in process for detection or control of insect vectors in indoor and outdoor environments.
    Type: Application
    Filed: February 16, 2012
    Publication date: August 14, 2014
    Applicant: CENTERS FOR DISEASE CONTROL AND PREVENTION
    Inventors: Roberto Barrera, Andrew J. Mackay, Manuel Amador
  • Patent number: 8795688
    Abstract: The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV2 strain.
    Type: Grant
    Filed: October 25, 2011
    Date of Patent: August 5, 2014
    Assignees: Sanofi Pasteur, Centers for Disease Control and Prevention
    Inventors: Richard Kinney, Claire Y. H. Kinney, VĂ©ronique Barban, Jean Lang, Bruno Guy
  • Publication number: 20140186357
    Abstract: A treatment method for degenerative brain disorders using a pharmaceutically effective dose of the inhibitor of SUMO1 (small ubiquitin-like modifier 1) and BACE1 (?-secretase) interaction, or the inhibitor of SUMO1 expression or activation is provided. More specifically, it was confirmed that SUMO1 increased BACE1 accumulation and A? generation, that is SUMO1 regulated BACE1 accumulation by interacting with BACE1, and BACE1 dileucine motif was involved in SUMO1-mediated BACE1 accumulation. In addition, SUMO1 protein induced autophagy in H4 cells, while SUMO1 depletion reduced LC3-II level. It was further confirmed that SUMO1 and LC3 were co-localized in the cortex of APP transgenic mice. As shown herein, a pharmaceutically effective dose of the inhibitor of SUMO1 and BACE1 interaction or the inhibitor of SUMO1 expression can be effectively used for the treatment of degenerative brain disorders.
    Type: Application
    Filed: September 9, 2013
    Publication date: July 3, 2014
    Applicant: KOREA CENTER FOR DISEASE CONTROL AND PREVENTION
    Inventors: Young Ho Koh, Sang Moon Yun, Sun-Jung Cho, Chulman Jo, Sangmee Ahn, Jae Chun Song, Sung Yeon Song